Uptravi was approved in 2016 to treat Pulmonary Arterial Hypertension, PAH.  We now have more than four years of experience with this medication.  There are three broad pathways that PAH medications impact.   3 Pathways PAH Medications Impact The endothelin pathway is overactive in PAH and leads to excessive blood vessel squeezing and … [Read more...]

Stem cells are special types of cells that have the ability to renew themselves and develop into different types of tissues.  There are a variety of different types of stem cells but the general concept is that we all have a small reservoir of these cells in our bodies.  These cells allow us to repair and replenish the cells that make up the different … [Read more...]

Excitement is building for the final release of the implanted system for Remodulin.  After more than 8 years of study, we are poised to have this device available to patients.  PAH patients across the country are eager to embrace the new pump and say goodbye to their Broviac/Hickman/Groshong catheter or their subcutaneous catheter and the associated site … [Read more...]

Sustained Release Beraprost This study looked at the addition of sustained release beraprost or placebo added to inhaled Tyvaso. United Therapeutics, the study sponsor, announced that there was no benefit found.  This will probably be the end of the road for the molecule beraprost. Many years ago the non-sustained release formulation was studied in PAH … [Read more...]

Although the progress of the implanted pump system for Remodulin has been a little like watching paint dry on the wall, we are inching closer to having this new system available for patients.  The clinical trial is now well into its eighth year.  The FDA has approved the pump and the catheter system.  United Therapeutics and Medtronic (the two companies that make the medication … [Read more...]